Earnings
Home›Earnings›Previews›Eli Lilly pulls further ahead of Novo Nordisk after la…
Eli Lilly pulls further ahead of Novo Nordisk after latest results
The latest earnings widened the gap in the obesity market, with Novo still working to regain market share and investor confidence in its pipeline.
CNBC Markets reports that the divide between Eli Lilly and Novo Nordisk is widening following their latest earnings, as Lilly extends its lead in obesity treatments.
According to CNBC World, Novo Nordisk is still racing to win back market share and restore investor confidence in its pipeline, suggesting the competitive balance remains unsettled.
The two companies are positioned differently going forward, with Lilly pushing further ahead while Novo focuses on convincing investors that its pipeline can reverse the recent traction loss.